Core Points - Apyx Medical Corporation granted a nonstatutory stock option to John Featherstone, Vice President of North American Sales, for 100,000 shares as an inducement for employment [1][2] - The stock option has an exercise price of $1.85, which is the closing price of Apyx Medical's common stock on the grant date [2] - The stock option vests over a four-year period, with 25% vesting on the first anniversary and the remainder vesting annually, contingent on continued employment [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market [3] - Renuvion and J-Plasma provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical documents [3] - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as Renuvion® and the AYON Body Contouring System™ for the cosmetic surgery market, as well as J-Plasma® for the hospital surgical market [3] - The company's technologies provide surgeons with the ability to deliver controlled heat to tissue, supported by over 90 clinical publications [3] Upcoming Events - Management will participate in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, in Boston, MA [1] - The President and CEO, Charlie Goodwin, along with CFO, Matt Hill, will engage in a fireside chat at 4:00 PM ET and will hold one-on-one meetings with investors throughout the day [2] Investor Relations - For further inquiries, the investor relations contact is Jeremy Feffer, Managing Director at LifeSci Advisors, reachable at 212-915-2568 or via email [4]

Core Viewpoint - Apyx Medical Corporation will release its financial results for Q2 of fiscal year 2025 on August 7, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 4:30 p.m. Eastern Time on the same day [2] - Interested parties can join the call by dialing 800-717-1738 or 646-307-1865 for international callers, using access code 35370 [2] - A live webcast of the call will be available on the company's website and will be archived for future reference [2] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products like Renuvion and the AYON Body Contouring System™ [3] - The company’s Helium Plasma Platform Technology is utilized in both cosmetic surgery and hospital surgical markets, providing surgeons with controlled heat to achieve desired results [3] - The effectiveness of Renuvion and J-Plasma is supported by over 90 clinical publications, showcasing the company's commitment to clinical validation [3] - Apyx Medical also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [3]

Core Insights - Apyx Medical Corporation is showcasing its Renuvion technology at Miami Swim Week, emphasizing real patient transformations and the empowerment of individuals through body contouring solutions [1][2][3] Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly its Helium Plasma Platform Technology, marketed as Renuvion, and the AYON Body Contouring System™ [5] - The company provides innovative products that enable surgeons to deliver controlled heat to tissue, supported by over 90 clinical documents [5] Product Highlights - Renuvion combines helium plasma and radiofrequency energy to achieve tissue contraction and collagen remodeling, making it a trusted tool for plastic surgeons globally [3] - The technology addresses loose skin concerns, which affect millions, offering a solution with minimal downtime [2][3] Marketing and Branding - The company aims to redefine beauty standards by highlighting real patient journeys and encouraging self-acceptance through its marketing efforts at major cultural events [3] - Apyx Medical's mission extends beyond aesthetics, focusing on restoring confidence to individuals struggling with loose skin [3]

The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 CLEARWATER, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion, is pleased ...